Muscle spasm is involuntary, sudden contraction of muscle or group of muscles of the body. Muscle spasm is also known as muscle cramp or involuntary hypertonicity. Muscle spasm usually occurs after muscular injury and is a sudden blast of high intensity pain, which ceases after five to ten minutes. Muscle spasm, in general condition, does not cause any chronic harm to the body. The most commonly affected muscles are lower leg muscles, front of the thigh and back of the thigh. Additionally, muscles of arms, feet, hands and abdomen are also affected, although the proportion is less.
The major causes of muscle spasm include muscular injury, spinal nerve compression, sprains and strains of the muscle (due to overuse) and diabetic ketoacidosis. Additionally, rickets, low blood potassium and sodium, animal instincts, and heat stroke are some of the other important causes of the condition. Since these cramps do not lead to any chronic condition, usually medical diagnosis and treatment is not advised. However, if the condition is persistent for longer period of time, a proper diagnosis is required. Blood test is a major diagnosis test (to understand thyroid functions, potassium and sodium levels) for muscle spasm. Additionally, electromyography is also performed to diagnose the disease.
The market of muscle spasm is segmented on the basis of drugs used to treat the condition, such as, diazepam, quinine, phenytoin, carbamazepine and others. Additionally, rehydration therapy, vitamin E, magnesium, calcium and niacin are also prescribed. The market is also segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW).
The North American region is the most dominating market in the world, owing to large incidences of muscle spasm, and rising focus towards R&D for muscle spasm treatments. On the other hand, Asia Pacific and RoW are the most promising markets in the upcoming period, owing to rise in awareness of muscle spasm, its causes and effects and its treatments.
The market of muscle spasm is likely to show steady growth during the forecast period from 2014 to 2020. This growth is likely to support by the factors such as increased athlete activities and thereby increased threat of muscle spasm, R&D activities and growing awareness of muscle spasm. Large number of exercise associated with muscle spasms is considered as an important driver of this market. For instance, according to the study conducted by the American Medical Society for Sports Medicine, 67% of triatheletes were suffered from exercise-associated muscle cramps (EAMC). Out of this, 50% were runners, whereas 15% were bikers. Additionally, due to R&D, drug formulations such as URG101 and others are under pipeline studies and are expected to enter in the market during the forecast period from 2014 to 2020. These drivers are likely to support the growth of muscle spasm market. On the other hand, limited diagnosis, self-limiting nature of the disease and high cost of R&D are some of the restraints of the market. Since the disease is self-limiting (maximum duration of cramp is around 10 minutes), usually people do not take any medicines. These factors are expected to hamper the market growth during the analysis period from 2014 to 2020.
Some of the major players operating in this market include Amgen, Inc., Eisai Co., Ltd., Novartis International AG, GlaxoSmithKline plc, AstraZeneca plc, Pfizer, Inc., and F. Hoffmann La Roche Ltd. amongst others.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments